Your browser doesn't support javascript.
loading
Liver Re-transplantation in Adults: Indications and Outcomes Analysis of a 23-year Experience in a Single Center in Argentina.
Bruballa, R; Sanchez Thomas, D; de Santl'banes, E; Ciardullo, M; Mattera, J; Pekolj, J; de Santibanes, M; Ardiles, V.
Affiliation
  • Bruballa R; General Surgery Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Sanchez Thomas D; General Surgery Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • de Santl'banes E; General Surgery Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Ciardullo M; General Surgery Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Mattera J; General Surgery Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Pekolj J; General Surgery Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • de Santibanes M; General Surgery Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
  • Ardiles V; Hepato-Pancreato-Biliary Surgery and Liver Transplantation Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.
Int J Organ Transplant Med ; 13(2): 30-35, 2022.
Article in En | MEDLINE | ID: mdl-37641732
ABSTRACT

Background:

Liver re-transplantation (re-LT) represents the only treatment for patients with irreversible graft failure.

Objective:

The aim of the current study was to describe the outcomes of both, patient and graft, after re- LT, at a high-volume referral center.

Methods:

Our population consisted of patients, with liver disease, who underwent re-LT in our institution between January 1996 and December 2019.

Results:

49 patients met the inclusion criteria. The patient's overall survival (OS) for the first year was 85% (Confidence Intervals (CI) 71-92) and 70% at five years (CI 53-82). In our population, three (6.12%) patients presented loss of graft and were included again in the transplant list; of these, one agreed to a new transplant while the remaining two died. This gave us graft survival results similar to those obtained for the re-LT patient; 85% at one year (CI 71-92) and 70% at 5 years (CI 53-82).

Conclusion:

Our study shows that re-LT is a valid and safe treatment for both early graft dysfunction and for transplanted patients who again present end-stage liver disease, showing a satisfactory long-term evolution, with parameters comparable to primary transplantation.
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Country/Region as subject: America do sul / Argentina Language: En Journal: Int J Organ Transplant Med Year: 2022 Document type: Article Affiliation country: Argentina

Full text: 1 Collection: 01-internacional Database: MEDLINE Country/Region as subject: America do sul / Argentina Language: En Journal: Int J Organ Transplant Med Year: 2022 Document type: Article Affiliation country: Argentina